Orbimed Advisors LLC Prelude Therapeutics Inc Transaction History
Orbimed Advisors LLC
- $4.24 Billion
- Q3 2024
A detailed history of Orbimed Advisors LLC transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Orbimed Advisors LLC holds 10,909,256 shares of PRLD stock, worth $14.6 Million. This represents 0.53% of its overall portfolio holdings.
Number of Shares
10,909,256
Previous 10,909,256
-0.0%
Holding current value
$14.6 Million
Previous $41.6 Million
45.67%
% of portfolio
0.53%
Previous 1.0%
Shares
3 transactions
Others Institutions Holding PRLD
# of Institutions
71Shares Held
35.7MCall Options Held
500Put Options Held
300-
Baker Bros. Advisors LP New York, NY10.1MShares$13.6 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$5.05 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$2.29 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$1.47 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.07MShares$1.43 Million0.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $48.7M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...